{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T17:14:06Z","timestamp":1655831646716},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3836,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Cardiol"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1002\/clc.4960280307","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T05:05:01Z","timestamp":1183007101000},"page":"136-142","source":"Crossref","is-referenced-by-count":19,"title":["Losartan and end-organ protection-lessons from the renaal study"],"prefix":"10.1002","volume":"28","author":[{"given":"Peter R.","family":"Kowey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania Z.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahnaz","family":"Shahinfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry M.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"10.1002\/clc.4960280307-BIB1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.281.14.1291","article-title":"Diabetes and decline in heart disease mortality in US adults","volume":"281","author":"Gu","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960280307-BIB2","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960280307-BIB3","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1161\/01.CIR.0000042673.07632.76","article-title":"Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study","volume":"106","author":"Djousse","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/clc.4960280307-BIB4","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0735-1097(02)02165-4","article-title":"Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes","volume":"40","author":"Diercks","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960280307-BIB5","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/clc.4960280307-BIB6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-137-7-200210010-00007","article-title":"Acute myocardial infarction and renal dysfunction: A high-risk combination","volume":"137","author":"Wright","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1002\/clc.4960280307-BIB7","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V122218","article-title":"Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study","volume":"12","author":"Ruilope","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1002\/clc.4960280307-BIB8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0735-1097(01)01470-X","article-title":"Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction","volume":"38","author":"Al-Ahmad","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1002\/clc.4960280307-BIB9","unstructured":"National Institutes of Health: US Renal Data System Report 2000, Section A, Incidence of Reported ESRD. 2000; 249-293"},{"key":"10.1002\/clc.4960280307-BIB10","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/01.CIR.0000035248.71165.EB","article-title":"Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes","volume":"106","author":"Herzog","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/clc.4960280307-BIB11","first-page":"S31","article-title":"Controlling the epidemic of cardiovascular disease in chronic renal disease: Report from the National Kidney Foundation Task Force on cardiovascular disease","volume":"9","author":"Meyer","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1002\/clc.4960280307-BIB12","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1007\/PL00002940","article-title":"Risk factors for cardiovascular mortality and morbidity: The WHO Multinational Study of Vascular Disease in Diabetes","volume":"44","author":"Fuller","year":"2001","journal-title":"Diabetologia"},{"key":"10.1002\/clc.4960280307-BIB13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1002\/clc.4960280307-BIB14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960280307-BIB15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3317\/jraas.2000.062","article-title":"The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)","volume":"1","author":"Brenner","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Sys"},{"key":"10.1002\/clc.4960280307-BIB16","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960280307-BIB17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death. Cardiovascular events and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/clc.4960280307-BIB18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/S0272-6386(04)00369-5","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","unstructured":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-290","journal-title":"Am J Kidney Dis"},{"key":"10.1002\/clc.4960280307-BIB19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1002\/clc.4960280307-BIB20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/clc.4960280307-BIB21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/clc.4960280307-BIB22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960280307","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/clc.4960280307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T05:20:03Z","timestamp":1629091203000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960280307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"URL":"https:\/\/doi.org\/10.1002\/clc.4960280307","relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}